BCL2 and B-cell chronic lymphocytic leukemia: In agreement with a previous study [15], VCX treatment led to a reduction of > 30% in BCL2 protein levels in MEC1, BJAB, CTL B cells, and primary CLL cells derived from 4 independent patients (Fig. S1).